Mark Pilling

Mark is a Senior Research Associate in the Behaviour and Health Research Unit (BHRU). He has a background within both academia (medical consultancy at Sheffield University & health-care research at Manchester University) and also the Pharmaceutical industry (statistical genetics, safety assessment & drug discovery for AstraZeneca, and clinical studies for GSK/Novartis). He has reviewed ~60 papers, a number of NIHR grants and is a panel member for a national grant awarding body. The majority of his ~40 publications relate to a variety of different types of late-stage healthcare studies.

Research Interests:

Mark’s work involves supporting all projects at the BHRU, covering such statistical techniques as meta-analysis, Bayesian meta-regression, generalized linear models, zero-inflated repeated-measures regression, hurdle models, GEE, GAMLSS, machine learning approaches, hierarchical models, Rasch analysis, assessing agreement, questionnaire development, survey data analysis,… These tools support his interest in the field of Healthcare Statistics and more specifically Trial Design.

Updated contact information: +44 1223 761313

Skype: dr.mark.pilling



– B.Sc. Mathematics, Durham, 1991

– M.Sc. Statistics, Sheffield, 1995

– Ph.D. Statistics & Ecology, Sheffield, 2001

Additional Information:

Mark is currently a committee member of Royal Statistical Society’s (RSS) Medical Statistics Section, and is a book reviewer for the RSS. He also sits on the grant assessment panel of the NC3Rs (National Centre for the Replacement, Refinement and Reduction of Animals in Research).

Additionally, Mark acts as an independent Statistician on trial steering and data monitoring & ethics committee (TSDMEC) for the “Caring for Me and You: A toolkit for carers of people with dementia” trial in Oxford, and also on the independent data monitoring committee for the “PreventIT” trial in Manchester. Within this role, he regularly gives presentations on statistical issues, and assists with Ph.D. students projects within the group.

Publications (Selected publications of most relevance/recency)

Impact of calorie labelling in worksite cafeterias: A stepped wedge randomised controlled pilot trial. M Vasiljevic, E Cartwright, M Pilling, MM Lee, G Bignardi, R Pechey, G Hollands, S  Jebb, & T Marteau. 2018. International Journal of Behavioural Nutrition and Physical Activity

A multi-center preclinical study of Gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function. A Karageorgis, S Lenhard, B Yerby, M Forsgren, S Liachenko, E Johansson, M Pilling, R Peterson, X Yang, D Williams, S Ungersma, R Morgan, K Brouwer, B Jucker, P Hockings. 2018. Plos One.

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. W Proctor, A Foster, J Vogt, C Summers, B Middleton, M Pilling, D Shienson, M Kijanska, S Ströbel, J Kelm, P Morgan, S Messner, D Williams. 2017. Arch Toxicol. 91(8), 2849-2863.

The contributions of family care-givers at end of life: A national post-bereavement census survey of cancer carers’ hours of care and expenditures. C Rowland, B Hanratty, M Pilling, B van den Berg, G Grande. 2017. Palliative Medicine 31(4), 346-355.

Feasibility study to prevent falls in older people who are sight impaired: the VIP2UK randomised controlled trial. H Waterman, C Ballinger, C Brundle, S Chastin, H Gage, R Harper, D Henson, B Laventure, L McEvoy, M Pilling, N Olleveant, D A Skelton, P Stanford, C Todd. 2016. Trials 17(1), 464.

The theoretical and practical determination of clinical cut-offs for the British Sign Language versions of PHQ-9 and GAD-7. R Belk, M Pilling, KD Rogers, K Lovell, A Young. 2016. BMC Psychiatry 16:372.

A randomised controlled feasibility trial of Group Cognitive Behavioural Therapy for people with severe asthma. J Yorke, P Adair, AM Doyle, L Dubrow-Marshall, S Fleming, L Holmes, A Menzies-Gow, R Niven, M Pilling & C Shuldham. 2016. Journal of Asthma.

Recommendations for managing missing data, attrition and response shift in palliative and end-of-life care research : Part of the MORECare research method guidance on statistical issues. N Preston, P Fayers, S Walters, M Pilling, G Grande, V Short, E Owen-Jones, C Evans, H Benalia, I Higginson, C Todd. 2013. Palliative Medicine 27(10) 899-907.

A study to assess the feasibility to undertake an RCT on adherence to eye drops in glaucoma patients. C Richardson, L Brunton, N Olleveant, DB Henson, M Pilling, J Mottershead, C Fennerty, AF Spencer, H Waterman. 2013. Patient Preference and Adherence 7, 1025–1039.

The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. C Farrell, SG Brearley, M Pilling, A Molassiotis. 2013. Supportive Care in Cancer 21 (1), 59-66.

An Exploratory Study to Clarify the Cluster of Symptoms Predictive of Chemotherapy-Related Nausea Using Random Forest Modeling. A Molassiotis, C Farrell, K Bourne, SG Brearley, M Pilling. 2012. Journal of Pain and Symptom Management 44(5), 692-703.